170 related articles for article (PubMed ID: 37943277)
1. Topical Treatments for Melasma and Post-inflammatory Hyperpigmentation.
Sadick N; Pannu S; Abidi Z; Arruda S
J Drugs Dermatol; 2023 Nov; 22(11):1118-1123. PubMed ID: 37943277
[TBL] [Abstract][Full Text] [Related]
2. A case report on the use of topical cysteamine 5% cream in the management of refractory postinflammatory hyperpigmentation (PIH) resistant to triple combination cream (hydroquinone, topical corticosteroids, and retinoids).
Mathe N; Balogun M; Yoo J
J Cosmet Dermatol; 2021 Jan; 20(1):204-206. PubMed ID: 32997864
[TBL] [Abstract][Full Text] [Related]
3. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J; Fabi S; Robinson D; Bajaj S; Geronemus R; Bell M; Widgerow A
J Drugs Dermatol; 2023 Apr; 22(4):333-338. PubMed ID: 37026875
[TBL] [Abstract][Full Text] [Related]
4. Topical Treatments for Photoaged Skin.
Sadick N; Pannu S; Abidi Z; Arruda S
J Drugs Dermatol; 2023 Sep; 22(9):867-873. PubMed ID: 37683070
[TBL] [Abstract][Full Text] [Related]
5. Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion.
Sofen B; Prado G; Emer J
Skin Therapy Lett; 2016 Jan; 21(1):1-7. PubMed ID: 27224897
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
Kaufman BP; Alexis AF
J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
[TBL] [Abstract][Full Text] [Related]
7. Comparing the Efficacy and Tolerability of Moderate to Severe Hyperpigmentation and Skin Unevenness.
Callender VD; Orlinsky D; Simmons-O'Brien E; Nwade NC; Rhodes T; Byrd AS
J Drugs Dermatol; 2024 Jan; 23(1):1260-1265. PubMed ID: 38206158
[TBL] [Abstract][Full Text] [Related]
8. Disparities in State Medicaid Coverage of Tretinoin for Pigmentary Disorders Compared to Acne Vulgaris.
Manjaly P; Kamal K; Ly S; Sanchez K; Getachew E; Mostaghimi A; Theodosakis N
J Drugs Dermatol; 2024 Jun; 23(6):e151-e153. PubMed ID: 38834215
[TBL] [Abstract][Full Text] [Related]
9. Treatment of melasma with topical agents, peels and lasers: an evidence-based review.
Rivas S; Pandya AG
Am J Clin Dermatol; 2013 Oct; 14(5):359-76. PubMed ID: 23881551
[TBL] [Abstract][Full Text] [Related]
10. Extension Phase of a Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang JV; Fabi SG; Robinson DM; Bajaj S; Geronemus RG; Bell M; Robison T; Widgerow AD
J Drugs Dermatol; 2024 Jan; 23(1):1266-1270. PubMed ID: 38206144
[TBL] [Abstract][Full Text] [Related]
11. Postinflammatory and rebound hyperpigmentation as a complication after treatment efficacy of telangiectatic melasma with 585 nanometers Q-switched Nd: YAG laser and 4% hydroquinone cream in skin phototypes III-V.
Lueangarun S; Namboonlue C; Tempark T
J Cosmet Dermatol; 2021 Jun; 20(6):1700-1708. PubMed ID: 33002283
[TBL] [Abstract][Full Text] [Related]
12. Oral Tranexemic Acid With Triple Combination Cream (Flucinolone+Hydroquinone+Tretinoin) Versus Triple Combination Cream Alone In Treatment Of Melasma.
Basit A; Rahman A; Uddin R
J Ayub Med Coll Abbottabad; 2021; 33(2):293-298. PubMed ID: 34137548
[TBL] [Abstract][Full Text] [Related]
13. Topical treatments for melasma and postinflammatory hyperpigmentation.
Lynde CB; Kraft JN; Lynde CW
Skin Therapy Lett; 2006 Nov; 11(9):1-6. PubMed ID: 17075653
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream.
Torok HM
Am J Clin Dermatol; 2006; 7(4):223-30. PubMed ID: 16901182
[TBL] [Abstract][Full Text] [Related]
15. Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice.
Callender VD; Baldwin H; Cook-Bolden FE; Alexis AF; Stein Gold L; Guenin E
Am J Clin Dermatol; 2022 Jan; 23(1):69-81. PubMed ID: 34751927
[TBL] [Abstract][Full Text] [Related]
16. Topical Stabilized Cysteamine as a New Treatment for Hyperpigmentation Disorders: Melasma, Post-Inflammatory Hyperpigmentation, and Lentigines.
Desai S; Hartman C; Grimes P; Shah S
J Drugs Dermatol; 2021 Dec; 20(12):1276-1279. PubMed ID: 34898155
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
Chan R; Park KC; Lee MH; Lee ES; Chang SE; Leow YH; Tay YK; Legarda-Montinola F; Tsai RY; Tsai TH; Shek S; Kerrouche N; Thomas G; Verallo-Rowell V
Br J Dermatol; 2008 Sep; 159(3):697-703. PubMed ID: 18616780
[TBL] [Abstract][Full Text] [Related]
18. Melasma in Latin America: options for therapy and treatment algorithm.
Cestari T; Arellano I; Hexsel D; Ortonne JP;
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):760-72. PubMed ID: 19646135
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.
Taylor SC; Torok H; Jones T; Lowe N; Rich P; Tschen E; Menter A; Baumann L; Wieder JJ; Jarratt MM; Pariser D; Martin D; Weiss J; Shavin J; Ramirez N
Cutis; 2003 Jul; 72(1):67-72. PubMed ID: 12889718
[TBL] [Abstract][Full Text] [Related]
20. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma.
Grimes PE
Cutis; 2007 Dec; 80(6):497-502. PubMed ID: 18246882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
